Get the Stockscreener App
0.0675
6.25%
-0.0045
Pre-market:
.07
0.0025
+3.70%
Conduit Pharmaceuticals Inc stock is traded at $0.0675, with a volume of 17.28M.
It is down -6.25% in the last 24 hours and down -9.64% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$0.072
Open:
$0.0727
24h Volume:
17.28M
Relative Volume:
0.36
Market Cap:
$10.38M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-1.2318
EPS:
-0.0548
Net Cash Flow:
-
1W Performance:
-26.63%
1M Performance:
-9.64%
6M Performance:
-71.65%
1Y Performance:
-97.64%
1-Day Range:
$0.065
$0.0728
1-Week Range:
$0.065
$0.093
52-Week Range:
$0.051
$3.92
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
0.0675 | 10.38M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Quotes, Forecast and News Summary - Benzinga
Conduit Pharmaceuticals secures stockholder approval By Investing.com - Investing.com Australia
Conduit Pharmaceuticals secures stockholder approval - Investing.com
Nasdaq Down Over 2%; Walgreens Posts Upbeat Results - Benzinga
Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December - Benzinga
Stock market today: IGM Biosciences plunged by 69.52% while XTI Aerospace down by 52.08% in early trading - Business Upturn
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Presidio Property Trust Announces Series D Preferred Stock Cash Dividend - The Manila Times
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Conduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse split - Investing.com India
Stock Plummets to Cents. Can the Company Bounce Back? - Jomfruland.net
Conduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock Split - TipRanks
Vela Technologies reports loss amid portfolio challenges By Investing.com - Investing.com Nigeria
Conduit and Sarborg link to optimise AI drug development - MSN
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics - The Manila Times
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial - The Bakersfield Californian
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and - EIN News
Conduit Pharmaceuticals Taps AI Revolution: Major Tech Partnership to Transform Drug Development - StockTitan
Presidio Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule - The Manila Times
Conduit Pharmaceuticals files to sell 75M shares of common stock for holders - MSN
Conduit Pharmaceuticals issues convertible note, amends Nirland agreement - Investing.com
Conduit Pharmaceuticals issues convertible note, amends Nirland agreement By Investing.com - Investing.com Canada
What's Going On With Conduit Pharmaceuticals Shares Today? - Benzinga
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders - The Manila Times
Conduit Pharmaceuticals receives further patent approval for AZD1656 - TipRanks
Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve
Conduit Pharmaceuticals reshuffles board and amends bylaws - Investing.com
Conduit Pharmaceuticals reshuffles board and amends bylaws By Investing.com - Investing.com UK
Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update - TipRanks
Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry | CDT Stock News - StockTitan
Conduit Pharmaceuticals announces restatement of financials - Investing.com
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Remitly Global Inc (NASDAQ: RELY) Is The Number One Stock Currently Moving. - Stocks Register
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Conduit Pharmaceuticals announces new addition to autoimmune pipeline - Yahoo Finance
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - StockTitan
Conduit Pharmaceuticals Opens New Lab Space In Cambridge, UK - Contract Pharma
Conduit Pharmaceuticals secures $1.2 million in funding - Investing.com India
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - The Manila Times
Conduit Pharmaceuticals secures $1.2 million in funding By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals announces debt restructuring and additional notes - MSN
LeMaitre to Participate at Upcoming Investor Conferences in November - The Manila Times
Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements - TipRanks
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN
Prologis Inc (NYSE: PLD): Forecast Strong In 2024, Up 18.49% - Stocks Register
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):